IL17RD
Overview
IL17RD (Interleukin 17 Receptor D, also known as SEF) is a negative regulator of FGF receptor signaling and has been described as an inhibitor of the PI3K/AKT pathway through its interaction with FGFR. In adenoid cystic carcinoma (ACC), IL17RD carries a somatic mutation, placing it in the intersection of FGFR and PI3K pathway biology that characterizes a subset of ACC tumors.
Alterations observed in the corpus
- Mutation observed in adenoid cystic carcinoma (ACC); IL17RD functions as a PI3K inhibitor via FGFR interaction, and its mutation may contribute to PI3K/FGFR pathway dysregulation in ACC PMID:23685749
Cancer types (linked)
- ACC (adenoid cystic carcinoma): somatic mutation detected in whole-exome sequencing study; functional consequence in ACC not characterized.
Co-occurrence and mutual exclusivity
- Mutation co-occurs in an ACC genomic landscape dominated by MYB-NFIB fusions and FGFR2 alterations; potential epistatic relationship with FGFR2 mutations not established PMID:23685749
Therapeutic relevance
- Not directly targeted in the corpus; loss of IL17RD-mediated PI3K inhibition could increase sensitivity to PI3K/AKT inhibitors or FGFR inhibitors in ACC.
Open questions
- Whether IL17RD mutation results in loss of FGFR-suppressive function and thereby cooperates with FGFR2 activating mutations in ACC has not been tested PMID:23685749
Sources
This page was processed by crosslinker on 2026-05-09.